Correlation between $B-RAF^{V600E}$ mutation and clinico–pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature

L Fugazzola, E Puxeddu, N Avenia, C Romei, V Cirello, A Cavaliere, P Faviana, D Mannavola, S Moretti, S Rossi, M Sculli, V Bottici, P Beck-Peccoz, F Pacini, A Pinchera, F Santeusanio and R Elisei

1Institute of Endocrine Sciences, University of Milan and Fondazione Policlinico IRCCS, Milan, Italy
2Internal Medicine Department and 3Endocrine Surgery Regional Referral Centre, University of Perugia, Perugia, Italy
4Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
5Department of Pathology, University of Perugia, Perugia, Italy
6Department of Oncology, University of Pisa, Pisa, Italy
7Pathology Unit, University of Milan, Ospedale San Paolo and Fondazione Policlinico IRCCS, Milan, Italy
8Departments of Internal Medicine, Endocrinology and Metabolism, and Biochemistry, University of Siena, Siena, Italy

(Requests for offprints should be addressed to L Fugazzola; E mail: l.fugazzola@policlinico.mi.it)

(L Fugazzola and E Puxeddu contributed equally to the work)

Abstract

Recently, a somatic point mutation of the $B-RAF$ gene (V600E) has been identified as the most common genetic event in papillary thyroid carcinoma (PTC), with a prevalence variable among different series. Since discordant data on the clinico-pathologic features of $B-RAF$ mutated PTC are present in the literature, the aim of the present co-operative study was to establish the prevalence of this genetic alteration and to perform a genotype–phenotype correlation in a large cohort of patients with PTC. To this purpose, a series of 260 sporadic PTCs with different histological variants were included in the study. The mutational analysis of the $B-RAF$ gene was performed either by RT-PCR followed by single-stranded conformational polymorphism or by PCR and direct sequencing. Statistical analyses were obtained by means of $\chi^2$/Fisher's exact test and t-test. Overall, a heterozygous T > A transversion at nucleotide 1799 (V600E) was found in 99 out of 260 PTCs (38%). According to the histological type of the tumor, the $B-RAF^{V600E}$ mutation was present in 48.3% of cases of classic PTCs (85 out of 176), in 17.6% (nine out of 51) of follicular variants of PTCs, in 21.7% (five out of 23) in other PTC variants and in none of the ten poorly differentiated tumors. $B-RAF^{V600E}$ was significantly associated with the classic variant of PTC ($P = 0.0001$) and with an older age at diagnosis ($P = 0.01$). No statistically significant correlation was found among the presence of $B-RAF^{V600E}$ and gender, tumor node metastasis (TNM), multicentricity of the tumor, stage at diagnosis and outcome. In conclusion, the present study reports the prevalence of $B-RAF^{V600E}$ (38%) in the largest series of sporadic PTCs, including 260 cases from three different Italian referring centers. This prevalence is similar to that calculated by pooling together all data previously reported, 39.6% (759 out of 1914 cases), thus indicating that the prevalence of this genetic event lies around 38–40%. Furthermore, $B-RAF^{V600E}$ was confirmed to be associated with the papillary growth pattern, but not with poorer differentiated PTC variants. A significant association of $B-RAF$ mutation was also found with an older age at diagnosis, the mutation being very rare in childhood and adolescent PTCs. Finally, no correlation was found with a poorer prognosis and a worse outcome after a median follow-up of 72 months.

Endocrine-Related Cancer (2006) 13 455–464
Introduction

Papillary thyroid carcinoma (PTC) is the most common type of endocrine tumor, with an annual incidence of two to four per 100,000 individuals. Among several oncogenes, RET (Santoro et al. 1992, Bongarzone et al. 1998) and, more recently, B-RAF (Cohen et al. 2003, Namba et al. 2003, Nikiforova et al. 2003, Peirko et al. 2005, Xing et al. 2004, 2005, Xing 2005, Xu et al. 2003) have been found frequently and alternatively activated in PTCs. Both genes act through the MAP kinase pathway, which seems to play a very central role in the pathogenesis of this tumor.

**B-RAF** mutations have been described at high frequency in melanoma (70%) and, with a lower prevalence (10–20%), also in colon and ovarian cancer, in lung and stomach cancer and in sarcomas (Davies et al. 2002). The prevalence of **B-RAF** mutated thyroid cancers varies between 23 and 62% among different series (reviewed in Fig. 1), this variability being related to the heterogeneity of the histological types of PTC, to epidemiological factors or to the age group analysed. With the exception of the mutation K601E found in one follicular adenoma and four PTC follicular variants (Trovisco et al. 2004, 2005), the gene rearrangement AKAP9-BRAF described in one sporadic and three radiation-associated PTCs (Ciampi et al. 2005), the three nucleotide deletion (K601del) found in three metastatic lymph nodes and in a solid variant of PTC (Oler et al. 2005, Trovisco et al. 2005) and the three nucleotide insertion (V599Ins) found in a classic variant of PTC (Carta et al. 2006), the amino acid change **B-RAF**V600E is the only mutation consistently found in PTC. This mutation is of great importance because the V600 residue significantly contributes to the stabilization of the inactive conformation of the B-Raf kinase domain.
The substitution of the valine with a glutamic acid (V600E) leads to the destabilization of the inactive conformation, promoting an active state and enhancing B-Raf kinase activity toward MEK (Wan et al. 2004, Wellbrock et al. 2004).

B-RAF mutations and ret/PTC rearrangements, which are present in about 20–40% of PTCs (Santoro et al. 1992, Bongarzone et al. 1998), have been shown to be mutually exclusive (Kimura et al. 2003, Soares et al. 2003, Frattini et al. 2004, Puxeddu et al. 2004). Moreover, compared with ret/PTCs, which are more frequently associated with post-Chernobyl tumors (Fugazzola et al. 1996, Elisei et al. 2001), B-RAF mutation is not a major event in irradiated PTCs (Lima et al. 2004, Nikiforova et al. 2004, Powell et al. 2005).

B-RAF mutations are present not only in papillary histotype, but also in anaplastic (Namba et al. 2003, Begum et al. 2004, Soares et al. 2004) and in poorly differentiated thyroid carcinomas, when a well-differentiated PTC component is present (Nikiforova et al. 2003). In the papillary histotype, B-RAF mutations are significantly associated with tumors with a papillary or mixed follicular–papillary growth pattern (Nikiforova et al. 2003, Fugazzola et al. 2004, Trovisco et al. 2004, 2005).

A correlation between older age at diagnosis and B-RAF(V600E) has been described (Nikiforova et al. 2003, Trovisco et al. 2005) and recently some authors have reported a low prevalence of B-RAF(V600E) in PTCs diagnosed in childhood (Kumagai et al. 2004, Lima et al. 2004, Penko et al. 2005, Powell et al. 2005, Rosenbaum et al. 2005). At present, no other unequivocal correlations between genotype and clinico-pathologic features of PTC patients have been reported both in previous reports from the present authors (Fugazzola et al. 2004, Puxeddu et al. 2004) and in other more recent studies (Sedliarou et al. 2004, Kim et al. 2005, Liu et al. 2005, Trovisco et al. 2005). A few studies (Namba et al. 2003, Nikiforova et al. 2003, Xing 2005, Xing et al. 2005) have shown a correlation of B-RAF(V600E) with more advanced stage, nodal/distant metastases at diagnosis or tumor recurrence. Correlation with the male gender has been reported in a single study (Xu et al. 2003). These discrepancies might be due to the heterogeneity of the histological variants of PTCs, to epidemiological factors, to the age group analyzed or to the small number of cases studied.

The aim of the present co-operative study was to correlate B-RAF(V600E) with several clinical and pathological features in a large and homogeneous cohort of 260 Italian PTC patients in order to better define the prevalence of the mutation and the statistically significant correlations.

Patients and Methods

Patients and tumor specimens

A series of 260 PTCs tissues were included in this study. In particular, the following histologic PTC variants were studied: classic (n = 176), follicular (n = 51), others (including tall cell, oncocytic and solid variants, n = 23) and poorly differentiated carcinomas, without well-differentiated components (n = 10). Samples were obtained consecutively at the time of surgery from the endocrine surgery units of the Universities of Milan, Perugia and Pisa, Italy. All tissues were snap frozen and archived at −80°C. In the three centers, histological diagnoses were carried out following the same criteria (LiVolsi 1990, LiVolsi et al. 2004, Rosai 2004) (Fig. 2) and cancers were staged according to the last tumor node metastasis (TNM) staging system from American Joint Committee on Cancer 2002 and International Classification of Diseases for Oncology (ICD-O C73). In order to limit the variability of different case sets subjected to diverse histopathological interpretations, 230 out of 260 glass slides were histologically re-examined, in a blind manner, by experienced pathologists at the participating centers. All tumors were sporadic and excised from patients not exposed to external radiation or radioactive fall-out. The remission, persistence or recurrence of the disease was evaluated for each patient by radioiodine total body scan, thyroglobulin and anti-thyroglobulin auto-antibody measurement either when off l-thyroxine treatment or after recombinant human thyrotropin stimulus (thyrogen, thyrotropin α; Genzyme Corporation, Cambridge, MA, USA), neck ultrasound and fine needle aspiration cytology on suspicious masses. Because of the slow progression of most PTCs, for the statistical analysis, only patients (n = 81) with a follow-up longer than 24 months (median follow-up 72 months) were considered.

In order to evaluate possible differences in B-RAF(V600E) prevalence according to the origin of the samples, patients were sub-classified as originating from the north, center or south of Italy.

Data from 104 out of 260 cases (40%) included in the present study have been reported previously.
Two different techniques were used for B-RAF analysis on the tumoral specimens. About half of the samples were analyzed using tumor DNA while the others were studied using tumor RNA. All procedures for handling the tissues were approved by each hospital ethics committee. Informed consent was obtained from all screened subjects.

DNA and RNA extraction from tissues

To ensure a pure tumor tissue isolation in tumors <1.5 cm, microdissection was performed. In larger tumors, the core of the tumoral nodule was dissected macroscopically and analyzed after histological confirmation of malignancy. DNA was extracted from tumor tissues by means of commercial kits (Puregene; Gentra Systems, Minneapolis, MN, USA). RNA extraction was performed using Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA), according to the manufacturer’s instructions.

PCR amplification and direct sequencing analysis

For B-RAF analysis, the DNA was PCR amplified using specific intronic primers (Xu et al. 2003) according to the following protocol: 35 cycles of denaturation (94°C for 1 min), annealing (60°C for 1 min) and extension (72°C for 2 min) on a TouchDown thermal cycler (Hybaid, Basingstoke,
Middx, UK). After purification, PCR products were directly sequenced. An aliquot of 3–10 ng/100 bp purified DNA and 3.2 pmol of either the forward or reverse primer were used in standard cycle sequencing reactions with ABI PRISM big dye terminators and run on an ABI PRISM 310 genetic analyzer (PE Applied Biosystems, Foster City, CA, USA). The cycle-sequencing conditions consisted of 25 cycles of 96°C for 30 s, 50°C for 15 s and 60°C for 4 min. One sequence read from each direction across the entire coding region and including intron–exon boundaries was obtained for each sample.

**Reverse transcription and single-stranded conformational polymorphism (SSCP) analysis**

Total RNA was submitted to reverse transcription with either AMV reverse transcriptase (Promega Corp., Madison, WI, USA) or Superscript reverse transcriptase II (Invitrogen Corp.) using a random hexamer mixture as primers. For each set of reactions a negative control tube containing double-distilled water and no nucleic acids was co-incubated.

All the cDNAs were submitted to a PCR using sets of primers designed to flank exon 15 of *B-RAF* (forward: CATTGCACGACAGACTGCAC; reverse: TCTGACTGAAAGCTGTATGG) according to the following protocol: 35 cycles of denaturation (95°C for 1 min), annealing (60°C for 1 min) and extension (72°C for 1 min) on an automated heat block (iCycler; BioRad, Hercules, CA, USA). Mutational analysis of PCR products was performed by SSCP screening. SSCP analysis was conducted using a method reported previously (Puxeddu et al. 2004). Briefly, 5 μl PCR product was mixed with 25 μl DNA gel-loading buffer (95% formamide, 20 mM NaOH, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol), denatured and loaded onto a 0.5 × mutation detection enhancement gel (MDE gel solution; Cambrex, Rockland, ME, USA) containing 10% glycerol. Gels were run in 0.6 × Tris–borate–EDTA buffer at 4 W overnight using a D-code universal mutation detection system (BioRad). Staining of the separated DNA bands on the gels was performed using the Gelstar nucleic acid gel stain (Cambrex). ARO and NPA human thyroid carcinoma cell lines were used as heterozygous and homozygous positive controls respectively, while WRO cells were used as negative control (Kimura et al. 2003). Direct forward and reverse sequencing of the PCR products showing a gel shift at SSCP analysis was conducted after purification with the Wizard SV gel and PCR clean-up system purification kit (Promega Corp.) on a 16 capillary DNA sequencer (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems) at GeneLab (ENEA Casaccia, Rome, Italy) using the same primers as the PCR amplification. The results of the mutation screening for *B-RAF* of each sample were confirmed in at least two independent experiments.

**Statistical analysis**

Correlations between *B-RAF* mutation and various clinico–pathologic parameters were analyzed in all 260 patients. The statistical analyses were obtained by means of *t*-test and *χ*²/Fisher’s exact test. The difference between two values was considered significant when *P* < 0.05. All tests were performed using the Statistical Package for Social Sciences for Windows (SPSS Inc., Chicago, IL, USA).

**Results**

**Genetic analysis of *B-RAF***

All mutations detected involved a T > A transversion at nucleotide 1799 (V600E) and were heterozygous. Overall, the *B-RAF* V600E mutation was found in 99 out of 260 PTCs (38%). It is worthy to note that about 40% of the negative samples (60 out of 161) were tested with the two methods (starting from RNA or from DNA) and the results were comparable. According to the histological type of tumor, the *B-RAF* V600E mutation was present in 48.3% of cases of classic PTC (85 out of 176), in 17.6% (nine out of 51) of follicular variants of PTC, in 21.7% (five out of 23) of other PTC variants and in none of the ten poorly differentiated tumors.

**Correlation analysis between *B-RAF* mutation and clinical parameters**

The correlation between *B-RAF* V600E and various clinico–pathologic parameters were examined (Table 1). The *B-RAF* V600E was significantly associated with the classic variant of PTC with respect to all the other variants (*P* = 0.0001). Moreover, *B-RAF* V600E was correlated with an older age at diagnosis (*P* = 0.01). It is worthy of note that only one out of ten patients ≤18 years of age harbored the *B-RAF* mutation. No statistically significant correlation of *B-RAF* V600E with gender, TNM, multicentricity of the tumor and stage of the
disease at diagnosis was found. It should be noted that a trend towards a greater proportion of patients with \( B-RAF^{\text{WT}} \) presenting at stage I was observed, but this was not statistically significant.

As far as the outcome is concerned, this was analysed in the 81 patients with a follow-up longer than 24 months (median 72 months). Also for this parameter, no correlation with the presence/absence of \( B-RAF \) mutation was revealed.

No significant differences were noted in the prevalence of \( B-RAF^{\text{V600E}} \) positive tumors according to the origin of patients from the three different areas of Italy (north, center and south), with the exception of patients coming from Umbria, a small mountainous region in the center of Italy. In this area the prevalence of \( B-RAF \) mutated tumors was significantly higher (35 out of 51 (69%) positive samples vs 64 out of 209 (31%), \( P < 0.0001 \)).

### Discussion

In the present homogeneous series of sporadic PTCs, which is the largest reported to date and included 260 cases from three different Italian referring centers, \( B-RAF^{\text{V600E}} \) mutation was found in 99 out of 260 patients (38%). In the literature, the prevalence of \( B-RAF \) varies between 23 and 62% among different series probably due to the heterogeneity of the histological variants of PTC, to epidemiological factors or to the age group analyzed. In Fig. 1, all the reports on \( B-RAF \) analyses in PTC have been considered, and the mean frequency per country was calculated. Pooling together all the data from the various cohorts, a prevalence of 39.6% (845 out of 2129 cases) was obtained, which is similar to that found in the present study, indicating that the prevalence of this genetic event in PTCs is around 38–40%.

According to previous data (Nikiforova et al. 2003, Fugazzola et al. 2004, Trovisco et al. 2004, 2005), \( B-RAF^{\text{V600E}} \) was detected mainly in the classic variant of PTC (\( P = 0.0001 \)), confirming that this mutation is strongly associated with the papillary growth pattern. Tumors with histological variants generally considered more aggressive (tall cells, oncocytic and solid variants) harbored, as expected (Frattini et al. 2004, Xing et al. 2005), a relatively high percentage of the \( B-RAF \) mutations (five out of 23, 21.7%) which was, however, not statistically significant (\( P = 0.1 \)). At variance, none of the ten poorly differentiated tumors displayed the \( B-RAF \) mutation (\( P = 0.01 \)). This result, even though
obtained in a relatively small cohort, is in agreement with previous observations indicating the absence of B-RAF mutation in this histological type when not associated with a well-differentiated component (Nikiforova et al. 2003, Soares et al. 2004). On the basis of this evidence, it is conceivable that PTC with a poorer differentiation might be associated with other pathogenic events.

A significant correlation of B-RAFV600E was found with an older age at presentation (P = 0.01), confirming the data obtained in the series reported by Nikiforova et al. (2003). Moreover, in accordance with the reported low prevalence of this genetic event in children (Kumagai et al. 2004, Lima et al. 2004, Penko et al. 2005, Powell et al. 2005, Rosenbaum et al. 2005), nine out of ten PTCs in patients ≤18 years of age were B-RAFWT. On the contrary, RET activation has been demonstrated to be more frequent in PTCs originating during the first three decades of life (Bongarzone et al. 1996). On the basis of these observations, it is possible to postulate that childhood PTCs are genetically different from adulthood PTCs.

As far as other possible correlations between B-RAFV600E and the clinical features of PTC patients are concerned, no statistically significant differences in gender, stage, TNM, multicentricity or recurrence between B-RAF mutated and non-mutated cases were found. These results are in agreement with those reported in other series (Kim et al. 2005, Liu et al. 2005, Trovisco et al. 2005). On the contrary, previous data on the association of B-RAF with a worse stage and/or local or distant metastases or recurrence (Namba et al. 2003, Nikiforova et al. 2003, Xing 2005, Xing et al. 2005) are not confirmed in the present large series. However, it is worth noting that the multivariate analysis, which was indeed performed only in one of these studies (Xing et al. 2005), clearly demonstrated that when the histological subtypes of the PTCs were included, the significance of B-RAF mutation association with all the other high-risk pathological features of the tumor was lost. With regard to the association between B-RAFV600E and cancer recurrence described recently by Xing et al. (2005) and not found in the present series, a possible explanation could reside in the different median follow-up of the two cohorts (15 months in the paper by Xing et al. (2005) and 72 months in the present study).

The analysis of the prevalence of B-RAFV600E according to the geographic origin of cases showed a significantly higher prevalence of B-RAFV600E (P < 0.0001) in the cohort of patients coming from Umbria. Since this group was not significantly different from the others coming from north, center and south of Italy concerning sex, age, TNM, histology and including the variant of the PTC, we are tempted to speculate that a genetic shared background in this small area or the particularly high iodine deficiency of this region could be the explanation for this intriguing finding.

In conclusion, in this study we found that 38% of PTCs in this large series of Italian cases harbored a B-RAFV600E mutation. This prevalence is highly comparable with the ‘worldwide’ mean prevalence. According to previous observations, this genetic event was found to be more frequently associated with the classic variant of PTC. Among all the other clinico-pathologic features that we analyzed B-RAFV600E was found to be correlated only with an older age at diagnosis. In particular, no correlation was found with a poorer prognosis and a worst outcome after a median follow-up of 72 months.

**Funding**

This study was supported in part by grants from Ministero della ISTRUZIONE UNIVERSITARIA E RICERCA Scientifica 2004 to RE, Associazione Italiana per la Ricerca sul Cancro 2005 to RE and AP and Fondazione Cassa di Risparmio di Perugia 2004–2007 to FS.

The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

**References**


